Predicting treatment response in stomach cancer with belly spread
Part of Cancer, Digestive system clinical trials.
This study looks at samples of blood and tissue from people with advanced stomach cancer that has spread to the belly lining. The goal is to find markers that predict how well a treatment combining HIPEC (heated chemotherapy in the belly) with immunotherapy (drugs that help your immune system fight cancer) works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach (or gastroesophageal junction) cancer confirmed by a biopsy.
- You are between 18 and 75 years old and are not pregnant (if female).
- You are generally active and able to care for yourself (ECOG score 0 or 1).
- Your cancer is HER2-negative (a lab test shows no excess HER2 protein).
- Your cancer has spread to the lining of your belly (peritoneal metastasis) with a PCI score of 20 or less.
- You have already received a combination of HIPEC and a PD-1/PD-L1 inhibitor as part of your treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining standard chemotherapy and immunotherapy (tirelizumab) with heated chemotherapy given directly into the belly. It aims to treat stomach cancer that has spread to the abdominal lining, and may help shrink or control the cancer.
This study tries to better predict how well patients do after heated chemotherapy placed in the abdomen during surgery for stomach or colon cancer that has spread to the lining of the abdomen. It may help doctors choose the best treatment plan and timing for future patients.
This trial studies a combination treatment for stomach cancer that has spread to the lining of the abdomen. It uses a special way to deliver heated chemotherapy directly into the abdomen, along with an immunotherapy drug that helps your immune system attack the cancer.
This trial combines heated chemotherapy directly into the abdomen (HIPEC) with standard chemotherapy and an immunotherapy drug to treat advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can shrink tumors and help patients live longer.
This study looks at stomach (or stomach–esophagus junction) cancer tissue, treatment details, and patient-reported experiences to better predict how you may respond to standard chemotherapy. It may help personalize future treatment by identifying markers that connect your tumor environment and your expected outcomes.
This trial uses advanced imaging (ultrasound and CT) plus a blood test to predict how well your stomach cancer will respond to chemotherapy given before surgery. The goal is to personalize your treatment and improve outcomes.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.